We can't find the internet
Attempting to reconnect
15235.1 PFLS-LS
HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci
Zusammenfassung
HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increase antibiotic susceptibility of multidrug resistant staphylococci
Weitere Texte
Abstract
A new and highly innovative treatment will be realized by a novel and patentable small molecule|combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic|staphylococci. The consortium integrates a screening platform, biophysical characterization of small|molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models,|to develop initial HIT compounds into preclinical candidates
Beteiligte
Marc Gitzinger
Wirtschaftspartner
BioVersys AG Marc Gitzinger Hochbergerstrasse 60c 4057 Basel BS CH
Rainer Riedl
Kontaktperson
rainer.riedl@zhaw.ch
ZHAW Rainer Riedl Einsiedlerstrasse 31 8820 Wädenswil ZH CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-07-31
- Enddatum
- 2015-07-31
- Bewilligte Gesamtkosten
- CHF 971582.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%